Traditional drug discovery methods are slow, expensive, and have a high failure rate due to the complexity of predicting how drugs will affect gene expression across multiple diseases. Existing approaches often lack the ability to rapidly screen and validate potential therapeutic candidates with high certainty.

Transcripta Bio has developed a platform that combines a proprietary Drug-Gene Atlas with Conductor AI to accelerate drug discovery. The Drug-Gene Atlas maps the effects of thousands of compounds on gene expression, while Conductor AI predicts gene expression responses to billions of novel compounds. This enables the rapid identification of therapeutic candidates that rebalance gene expression to treat disease. The platform virtually screens billions of compounds for disease-modifying ability and off-target effects, and then synthesizes and tests new candidates in its lab to identify and de-risk novel therapies.

Drug-Gene Atlas: Maps molecular structure and drug action to the whole cell transcriptome.

Conductor AI: An AI modeling suite that discovers and predicts the effects of new drugs at transcriptome scale.

Virtual Screening: Screens billions of compounds for disease-modifying ability and off-target effects.

High-throughput Screening: Screens thousands of molecules across 20,000 genes to map chemical structure to gene expression.

Rapid Synthesis and Testing: Quickly synthesizes and tests new candidates in its lab to identify and de-risk novel therapies.

Target Certainty: Provides high target certainty with hard genetic evidence.

The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions involved in drug discovery and development.